# US 2021/0330722 A1 · Bacteriophage compositions for treating pseudomonas infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330722 A1
- Document ID: US20210330722A1
- Status: Published application
- Kind: A1
- Application number: 17/241,957
- Filed: 2021-04-27
- Published: 2021-10-28
- Earliest claimed: 2020-04-27
- Assignees: Armata Pharmaceuticals, Inc.
- Applicants: Armata Pharmaceuticals, Inc.
- Inventors: Sebastien Lemire; Stacey Lynn Kolar; Brian C. Varnum
- Web page: https://patentgrep.com/patent/US20210330722A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2795/10121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10171: Demonstrated in vivo effect
- C12N 2795/10221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10271: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to bacteriophages and compositions capable of infecting and killing Pseudomonas, and use of the same for treating Pseudomonas, e.g. Pseudomonas aeruginosa, bacterial infections.

## Claims

### Claim 1

A bacteriophage composition comprising one or more bacteriophages comprising a polynucleotide sequence selected from the polynucleotide sequence of SEQ ID NO: 1, a polynucleotide sequence of SEQ ID NO: 2, a polynucleotide sequence of SEQ ID NO: 3, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2, and/or a polynucleotide sequence with at least 90% identity to SEQ ID NO: 3.

### Claim 2 (depends on 1)

The bacteriophage composition of claim 1, comprising two or more bacteriophages, wherein a first bacteriophage of the two or more bacteriophages comprises a polynucleotide sequence selected from the polynucleotide sequence of SEQ ID NO: 1, a polynucleotide sequence of SEQ ID NO: 2, or a polynucleotide sequence of SEQ ID NO: 3, and wherein a second bacteriophage of the two or more bacteriophages comprises a naturally occurring phage.

### Claim 3 (depends on 1)

The bacteriophage composition of claim 1, comprising two or more bacteriophages comprising a polynucleotide sequence selected from the polynucleotide sequence of SEQ ID NO: 1, the polynucleotide sequence of SEQ ID NO: 2, the polynucleotide sequence of SEQ ID NO: 3, the polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, the polynucleotide sequence with at least 90% identity to SEQ ID NO: 2, and/or the polynucleotide sequence with at least 90% identity to SEQ ID NO: 3; wherein the composition's target bacteria range is broader than the cumulative range of the individual bacteriophages in the composition; and wherein the target bacteria range is broadened within a bacterial species that the bacteriophage is able to infect.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The bacteriophage composition of claim 1, further comprising at least one bacteriophage comprising a polynucleotide sequence selected from the polynucleotide sequence of SEQ ID NO: 4, the polynucleotide sequence of SEQ ID NO: 5, the polynucleotide sequence of SEQ ID NO: 6, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 4, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 5, and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 6.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The bacteriophage composition of claim 6, comprising two or more bacteriophages, wherein a first bacteriophage of the two or more bacteriophages comprises a polynucleotide sequence selected from the polynucleotide sequence of SEQ ID NO: 4, a polynucleotide sequence of SEQ ID NO: 5, or a polynucleotide sequence of SEQ ID NO: 6, and wherein a second bacteriophage of the two or more bacteriophages comprises a naturally occurring phage.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The bacteriophage composition of claim 8, wherein the composition's target bacteria range is broader than the cumulative range of the individual bacteriophage in the composition, and wherein the target bacteria range is broadened within the bacterial species that the bacteriophage is able to infect.

### Claim 11

(canceled)

### Claim 12 (depends on 13)

The isolated, purified bacteriophage of claim 13, comprising a polynucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22.

### Claim 13

An isolated, purified bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56 (depends on 13)

The bacteriophage of claim 13, wherein the bacteriophage is resistant to sputum inactivation, persists in the lung and/or bronchoalveolar lavage fluid up to 96 hours after administration, and/or maintains activity in the presence of a pulmonary treatment selected from salbutamol, tobramycin, aztreonam, colistin, inhaled hypertonic saline, and inhaled beta-agonist.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

A bacteriophage composition comprising two or more bacteriophages, wherein at least one of the bacteriophages comprises a polynucleotide sequence having at least 90% identity to a sequence selected from the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22; and wherein at least one other bacteriophage infects a Pseudomonas bacterium.

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62 (depends on 59)

The bacteriophage composition of claim 59, wherein the composition comprises at least one bacteriophage comprising a sequence selected from the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22.

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

A bacteriophage composition comprising one or more bacteriophages comprising a polynucleotide sequence having 90% to 100% identity to a sequence selected from the polynucleotide sequence of SEQ ID NO: 1, a polynucleotide sequence of SEQ ID NO: 2, a polynucleotide sequence of SEQ ID NO: 3, a polynucleotide sequence of SEQ ID NO: 4, a polynucleotide sequence of SEQ ID NO: 5, a polynucleotide sequence of SEQ ID NO: 6, a polynucleotide sequence of SEQ ID NO: 7, a polynucleotide sequence of SEQ ID NO: 8, a polynucleotide sequence of SEQ ID NO: 9, a polynucleotide sequence of SEQ ID NO: 10, a polynucleotide sequence of SEQ ID NO: 11, a polynucleotide sequence of SEQ ID NO: 12, a polynucleotide sequence of SEQ ID NO: 13, a polynucleotide sequence of SEQ ID NO: 14, a polynucleotide sequence of SEQ ID NO: 15, a polynucleotide sequence of SEQ ID NO: 16, a polynucleotide sequence of SEQ ID NO: 17, a polynucleotide sequence of SEQ ID NO: 18, a polynucleotide sequence of SEQ ID NO: 19, a polynucleotide sequence of SEQ ID NO: 20, a polynucleotide sequence of SEQ ID NO: 21, and a polynucleotide sequence of SEQ ID NO: 22.

### Claim 66 (depends on 65)

The bacteriophage composition of claim 65, comprising two or more bacteriophages selected from the polynucleotide sequence of SEQ ID NO: 1, a polynucleotide sequence of SEQ ID NO: 2, a polynucleotide sequence of SEQ ID NO: 3, a polynucleotide sequence of SEQ ID NO: 4, a polynucleotide sequence of SEQ ID NO: 5, or a polynucleotide sequence of SEQ ID NO: 6.

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71 (depends on 65)

The bacteriophage composition of claim 65 wherein the bacteriophage comprises a polynucleotide sequence with at least a 90% identity to SEQ ID NO: 7, a polynucleotide with at least a 93% identity to SEQ ID NO: 8, a polynucleotide sequence with at least 93% identity to SEQ ID NO: 9, a polynucleotide sequence with at least 89% identity to SEQ ID NO: 10, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 11, a polynucleotide sequence with at least 91% identity to SEQ ID NO: 12, a polynucleotide sequence with at least 92% identity to SEQ ID NO: 13, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 14 a polynucleotide sequence with at least 95% identity to SEQ ID NO: 15, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 16, a polynucleotide sequence with at least 92% identity to SEQ ID NO: 17, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 18, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 19, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 20, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 21, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 22.

### Claim 72

(canceled)

### Claim 73 (depends on 1)

The bacteriophage composition of claim 1, further comprising a storage medium for storage at room temperature or a temperature at or below 8° C., wherein the storage medium comprises a cryoprotectant.

### Claim 74

(canceled)

### Claim 75 (depends on 1)

The bacteriophage composition of claim 1, wherein the bacteriophage is resistant to sputum inactivation, remains in the lung and/or bronchoalveolar lavage fluid up to 96 hours after administration, and/or maintains activity in the presence of a pulmonary treatment selected from salbutamol, tobramycin, aztreonam, colistin, inhaled hypertonic saline, and inhaled beta-agonist.

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78 (depends on 1)

The bacteriophage composition of am claim 1, wherein one or more bacteriophages belong to the Family Podoviridae or Myoviridae.

### Claim 79

(canceled)

### Claim 80 (depends on 78)

The bacteriophage composition of claim 78, wherein one or more phage belong to the Family Myoviridae, Genus Pbunavirus, Genus Pakpunavirus, and/or Genus Nankokuvirus.

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84 (depends on 78)

The bacteriophage composition of claim 78, wherein one or more phage belong to the Family Podoviridae, Genus Phikmvvirus, Genus Litunavirus, Genus Bruynoghevirus, and/or Genus Luzseptimavirus.

### Claim 85

(canceled)

### Claim 86

(canceled)

### Claim 87

(canceled)

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90

(canceled)

### Claim 91

(canceled)

### Claim 92

(canceled)

### Claim 93

(canceled)

### Claim 94

(canceled)

### Claim 95

(canceled)

### Claim 96

(canceled)

### Claim 97

(canceled)

### Claim 98

(canceled)

### Claim 99

(canceled)

### Claim 100 (depends on 1)

The bacteriophage composition of claim 1, wherein the composition is substantially free of a bacterial component, and wherein the bacterial component comprises bacterial host protein and/or exotoxin.

### Claim 101

(canceled)

### Claim 102 (depends on 1)

The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.

### Claim 103 (depends on 1)

The composition of claim 1, wherein the composition is formulated for nebulization.

### Claim 104 (depends on 1)

The composition of claim 1, wherein the composition is a liquid, semi-liquid, solid, frozen, freeze-dried, cryodesiccated, or lyophilized formulation

### Claim 105 (depends on 1)

The composition of claim 1, wherein the bacteriophage of the composition targets one or more of Pseudomonas aeruginosa, antibiotic-resistant Pseudomonas aeruginosa, and multiple antibiotic-resistant Pseudomonas aeruginosa; and/or wherein the bacteriophages infect and kill one or more of Pseudomonas aeruginosa, antibiotic-resistant Pseudomonas aeruginosa, and multiple antibiotic-resistant Pseudomonas aeruginosa.

### Claim 106

(canceled)

### Claim 107 (depends on 1)

The composition of claim 1, wherein the composition comprises between 1×108 and 1×1011 PFU per milliliter of each bacteriophage.

### Claim 108 (depends on 1)

The composition of claim 1, wherein the composition is to be administered at a dosage of at least 3×108 PFU of total bacteriophages per milliliter per dose.

### Claim 109 (depends on 1)

The composition of claim 1, wherein the composition is stored at a temperature ranging from −80° C. to 25° C.

### Claim 110 (depends on 109)

The composition of claim 109, wherein the composition is stored at 2° C. to 8° C.

### Claim 111 (depends on 1)

The composition of claim 1, wherein at least one bacteriophage is obligately lytic.

### Claim 112 (depends on 1)

The bacteriophage or composition of claim 1, wherein the sequence of at least one bacteriophage is genetically modified.

### Claim 113

A bacteriophage composition comprising, consisting essentially of, or consisting of a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 1, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 2, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 3, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 4, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 5, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 6, and one or more bacteriophages selected from a bacteriophage comprising a polynucleotide sequence with 90%-100% identity to a sequence of SEQ ID NO: 4, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 5, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 6, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 7, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 8, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 9, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 10, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 11, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 12, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 13, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 14, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 15, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 16, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 17, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 18, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 19, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 20, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 21, and/or a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 22.

### Claim 114

(canceled)

### Claim 115

(canceled)

### Claim 116

(canceled)

### Claim 117

(canceled)

### Claim 118

(canceled)

### Claim 119

(canceled)

### Claim 120

(canceled)

### Claim 121

(canceled)

### Claim 122

(canceled)

### Claim 123

(canceled)

### Claim 124

(canceled)

### Claim 125

(canceled)

### Claim 126

(canceled)

### Claim 127 (depends on 1)

The bacteriophage composition of claim 1, wherein the bacteriophages reduce biofilm mass.

### Claim 128

(canceled)

### Claim 129

(canceled)

### Claim 130

(canceled)

### Claim 131

(canceled)

### Claim 132

(canceled)

### Claim 133

(canceled)

### Claim 134

(canceled)

### Claim 135

(canceled)

### Claim 136

(canceled)

### Claim 137

(canceled)

### Claim 138

(canceled)

### Claim 139

(canceled)

### Claim 140

(canceled)

### Claim 141

(canceled)

### Claim 142 (depends on 1)

A method of treating a bacterial infection comprising administering the bacteriophage or composition of claim 1.

### Claim 143

(canceled)

### Claim 144

(canceled)

### Claim 145

(canceled)

### Claim 146

(canceled)

### Claim 147

(canceled)

### Claim 148

(canceled)

### Claim 149

A method of treating a subject with a bacterial infection comprising selecting a bacteriophage based upon resistance to sputum inactivation and administering said bacteriophage to the subject, wherein the bacteriophage is selected from a bacteriophage comprising a polynucleotide sequence having at least 90% identity to a polynucleotide sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and/or SEQ ID NO: 22.

### Claim 150

(canceled)

### Claim 151

(canceled)

### Claim 152

(canceled)

### Claim 153

(canceled)

### Claim 154

(canceled)

### Claim 155

(canceled)

### Claim 156

(canceled)

### Claim 157

(canceled)

### Claim 158

(canceled)

### Claim 159

(canceled)

### Claim 160

(canceled)

### Claim 161

(canceled)

### Claim 162

(canceled)

### Claim 163

(canceled)

### Claim 164

(canceled)

### Claim 165

(canceled)

### Claim 166

(canceled)

### Claim 167

(canceled)

### Claim 168

(canceled)

### Claim 169 (depends on 149)

The method of claim 149, wherein the bacterial infection comprises a pulmonary infection, and/or rhinosinusitis, is in the presence of cystic fibrosis, non-cystic fibrosis bronchiectasis (NCFB), a lung fibrosis condition and/or pneumonia.

### Claim 170

(canceled)

### Claim 171

(canceled)

### Claim 172

(canceled)

### Claim 173

(canceled)

### Claim 174

(canceled)

### Claim 175

(canceled)

### Claim 176

(canceled)

### Claim 177

(canceled)

### Claim 178

(canceled)

### Claim 179

(canceled)

### Claim 180

(canceled)

### Claim 181

(canceled)

### Claim 182

(canceled)

### Claim 183

(canceled)

### Claim 184

(canceled)

### Claim 185

(canceled)

### Claim 186

(canceled)

### Claim 187

(canceled)

### Claim 188

(canceled)

### Claim 189

A bacterial host manufacturing strain comprising a bacteriophage selected from a bacteriophage comprising a polynucleotide sequence having 85%-100% identity to a sequence of SEQ ID NO: 1-22.

### Claim 190

(canceled)

### Claim 191

(canceled)

### Claim 192

(canceled)

### Claim 193

(canceled)

### Claim 194

(canceled)

### Claim 195

(canceled)

### Claim 196

(canceled)

### Claim 197

(canceled)

### Claim 198

(canceled)

### Claim 199

(canceled)

### Claim 200

(canceled)

### Claim 201

(canceled)

### Claim 202

(canceled)

### Claim 203

(canceled)

### Claim 204

(canceled)

### Claim 205

(canceled)

### Claim 206 (depends on 13)

The bacteriophage of claim 13, comprising a polynucleotide sequence with at least 93% but not 100% identity to any one of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

### Claim 207 (depends on 13)

The bacteriophage of claim 13, wherein the bacteriophage is not a naturally occurring phage.
